Carindacillin
{{Short description|Chemical compound}}
{{cs1 config|name-list-style=vanc}}
{{Drugbox
| IUPAC_name = (2S,5R,6R)-6-([3-(2,3-dihydro-1H-inden-5-yloxy)-3-oxo-2-phenylpropanoyl]amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
| image = Carindacillin.svg
| tradename =
| Drugs.com = {{drugs.com|international|carindacillin}}
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status = Rx-only
| routes_of_administration = Oral
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| index2_label = salt
| CAS_number2_Ref = {{cascite|correct|CAS}}
| CAS_number2 = 26605-69-6
| UNII2_Ref = {{fdacite|correct|FDA}}
| UNII2 = 4OUL81K2RT
| CAS_number = 35531-88-5
| ATC_prefix = J01
| ATC_suffix = CA05
| ATC_supplemental =
| PubChem = 93184
| DrugBank =
| ChEMBL = 1200991
| ChemSpiderID = 391995
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5V278481KE
| chemical_formula =
| C=26 | H=26 | N=2 | O=6 | S=1
| smiles = [Na+].O=C([O-])[C@@H]4N5C(=O)[C@@H](NC(=O)C(c1ccccc1)C(=O)Oc2cc3c(cc2)CCC3)[C@H]5SC4(C)C
}}
Carindacillin (INN), also known as carbenicillin indanyl (USAN), is a penicillin antibiotic. It is a prodrug of carbenicillin.{{cite journal |vauthors=English AR, Retsema JA, Ray VA, Lynch JE |title=Carbenicillin indanyl sodium, an orally active derivative of carbenicillin |journal=Antimicrob. Agents Chemother. |volume=1 |issue=3 |pages=185–91 |date=March 1972 |pmid=4558137 |pmc=444190 |doi= 10.1128/aac.1.3.185|url=}}
It is administered orally, as the sodium salt. It was formerly marketed in the United States by Pfizer under the brand name Geocillin. Pfizer withdrew Carindacillin from the U.S. market sometime after 2008.{{Cite web |title=Drugs@FDA: FDA-Approved Drugs CARBENICILLIN INDANYL SODIUM |url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050435 |archive-url=https://web.archive.org/web/20220729071701/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050435 |url-status=dead |archive-date=July 29, 2022 |access-date=2022-07-29 |website=www.accessdata.fda.gov}}
Pharmacokinetics
Shortly after absorption via the small intestine, carindacillin is hydrolyzed into carbenicillin. Carbenicillin acts by interfering with final cell wall synthesis in susceptible bacteria, including Pseudomonas aeruginosa, Escherichia coli, and some Proteus. The most common adverse effects include nausea, bad taste, diarrhea, vomiting, flatulence, and glossitis. Carindacillin was approved for use in adults in the treatment of prostatitis and urinary tract infections. Dosing was between 2000 and 4000 mg daily, divided into equally spaced doses.{{Cite web |last=Pfizer |date=2008 |title=GEOCILLIN® carbenicillin indanyl sodium tablets label |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050435s009lbl.pdf}}